GoodRx Q2 Earnings Fall Short of Expectations with EPS at 4c
ByAinvest
Friday, Aug 8, 2025 5:57 am ET1min read
GDRX--
The medication savings platform saw a 1% year-over-year (YoY) increase in revenue, driven by a 32% growth in pharma manufacturer solutions revenue to $35.0 million. However, prescription transactions revenue decreased by 3% to $143.1 million, primarily due to a 14% decline in Monthly Active Consumers, attributed to changes in the retail pharmacy landscape, including store closures and volume reduction in integrated savings programs [2].
CEO Wendy Barnes expressed excitement about the company's progress, highlighting new deals with pharmaceutical manufacturers and the launch of a condition-specific subscription product for erectile dysfunction. This new offering aims to reduce friction in the healthcare system and serve as a complement to insurance.
Despite the near-term challenges, GoodRx expects pharma manufacturer solutions to grow as a percentage of total revenue in the near to medium term. The company forecasts adjusted EBITDA between $265-$275 million for the full year 2025, representing 2-6% growth over 2024 [2].
GoodRx repurchased 10.2 million shares of Class A common stock for $46.4 million during the quarter, with $143.0 million remaining in its share repurchase program.
References:
[1] https://www.investing.com/news/earnings/goodrx-shares-tumble-as-q2-earnings-miss-expectations-93CH-4174853
[2] https://www.tradingview.com/news/tradingview:ae1287654b1a0:0-goodrx-holdings-inc-sec-10-q-report/
GoodRx reported Q2 EPS of 4c, missing consensus of 10c, and revenue of $203.1M, also below consensus of $205.71M. CEO Wendy Barnes expressed excitement about the company's progress, citing new deals with pharma and the launch of a condition subscription product for erectile dysfunction. The company aims to reduce friction in the healthcare system and serve as a complement to insurance.
GoodRx Holdings, Inc. (NASDAQ: GDRX) reported its second-quarter earnings on July 2, 2025, which fell short of analyst expectations. The company's earnings per share (EPS) of $0.04 missed the consensus estimate of $0.10, while revenue of $203.1 million was also below the expected $205.87 million [1].The medication savings platform saw a 1% year-over-year (YoY) increase in revenue, driven by a 32% growth in pharma manufacturer solutions revenue to $35.0 million. However, prescription transactions revenue decreased by 3% to $143.1 million, primarily due to a 14% decline in Monthly Active Consumers, attributed to changes in the retail pharmacy landscape, including store closures and volume reduction in integrated savings programs [2].
CEO Wendy Barnes expressed excitement about the company's progress, highlighting new deals with pharmaceutical manufacturers and the launch of a condition-specific subscription product for erectile dysfunction. This new offering aims to reduce friction in the healthcare system and serve as a complement to insurance.
Despite the near-term challenges, GoodRx expects pharma manufacturer solutions to grow as a percentage of total revenue in the near to medium term. The company forecasts adjusted EBITDA between $265-$275 million for the full year 2025, representing 2-6% growth over 2024 [2].
GoodRx repurchased 10.2 million shares of Class A common stock for $46.4 million during the quarter, with $143.0 million remaining in its share repurchase program.
References:
[1] https://www.investing.com/news/earnings/goodrx-shares-tumble-as-q2-earnings-miss-expectations-93CH-4174853
[2] https://www.tradingview.com/news/tradingview:ae1287654b1a0:0-goodrx-holdings-inc-sec-10-q-report/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet